Tirzepatide

Phase 2Recruiting

1 views this week 0 watching⚡ Active

Interest: 42/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Obesity

Conditions

Obesity, Overweight and Obesity, Overweight

Trial Timeline

Nov 9, 2023 → Dec 1, 2029

NCT ID

NCT05912621

About Tirzepatide

Tirzepatide is a phase 2 stage product being developed by Eli Lilly for Obesity. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05912621. Target conditions include Obesity, Overweight and Obesity, Overweight.

What happened to similar drugs?

20 of 20 similar drugs in Obesity were approved

Approved (20) Terminated (5) Active (0)

✅exenatide + PlaceboEli LillyApproved

✅TirzepatideEli LillyApproved

✅Micafungin + MicafunginAstellas PharmaApproved

✅MicafunginAstellas PharmaApproved

✅Zonegran + PlaceboEisaiApproved

✅lorcaserin hydrochloride XR + PlaceboEisaiApproved

✅Placebo + TirzepatideEli LillyApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (19)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07438444	Approved	Recruiting	Mar 1, 2026	Oct 1, 2027	Diabetes Mellitus, Type 2
NCT07299084	Phase 1	Recruiting	Jan 14, 2026	Oct 1, 2026	Diabetes Mellitus, Type 2
NCT07247084	Approved	Recruiting	Nov 24, 2025	Jul 1, 2032	Obesity
NCT06857942	Approved	Recruiting	Mar 19, 2025	May 1, 2028	Psoriasis
NCT06864026	Approved	Recruiting	Mar 6, 2025	Nov 1, 2027	Psoriatic Arthritis
NCT06635057	Approved	Active	Oct 11, 2024	Apr 1, 2026	Type 2 Diabetes
NCT05912621	Phase 2	Recruiting	Nov 9, 2023	Dec 1, 2029	Obesity
NCT05978713	Phase 1	Completed	Jul 31, 2023	Mar 12, 2024	Healthy
NCT05810597	Phase 1	Completed	Apr 3, 2023	Jul 17, 2023	Healthy
NCT05706506	Approved	Completed	Mar 8, 2023	Oct 31, 2023	Type 2 Diabetes
NCT04844918	Phase 3	Completed	May 10, 2021	Jun 24, 2023	Obesity
NCT04847557	Phase 3	Completed	Apr 20, 2021	Jul 2, 2024	Obesity
NCT04657003	Phase 3	Completed	Mar 29, 2021	Apr 10, 2023	Type 2 Diabetes
NCT04660643	Phase 3	Completed	Mar 29, 2021	May 18, 2023	Obesity
NCT04657016	Phase 3	Completed	Mar 29, 2021	May 12, 2023	Obesity
NCT04050670	Phase 1	Completed	Sep 13, 2019	Apr 3, 2020	Healthy
NCT04004988	Phase 1	Completed	Aug 19, 2019	Dec 16, 2019	Healthy
NCT03940742	Phase 1	Completed	Jul 22, 2019	Sep 22, 2020	Hepatic Insufficiency
NCT03482024	Phase 1	Completed	Mar 30, 2018	Aug 19, 2019	Renal Insufficiency

Competing Products

20 competing products in Obesity

See all competitors

Product	Company	Stage	Hype Score
MK0493	Merck	Phase 2	35
MK0557	Merck	Phase 3	40
AMG 786	Amgen	Phase 1	29
Bimagrumab + Tirzepatide + Bimagrumab Placebo + Tirzepatide Placebo	Eli Lilly	Phase 2	39
exenatide + Placebo	Eli Lilly	Approved	43
Brenipatide	Eli Lilly	Phase 1	36
Orforglipron + Placebo	Eli Lilly	Phase 3	47
TERN-601	Terns Pharmaceuticals	Phase 2	32
MBX 4291 + Placebo	MBX Biosciences	Phase 1	30
PG-102	Rani Therapeutics	Phase 1	26
Orforglipron + Placebo	Eli Lilly	Phase 1	29
Tirzepatide + Placebo	Eli Lilly	Phase 3	40
Eloralintide + Placebo	Eli Lilly	Phase 1	29
Oral Azelaprag (BGE-105) + Oral Placebo for Azelaprag (BGE-105) + Tirzepatide + Tirzepatide Placebo	Eli Lilly	Phase 2	27
LY3437943 + Midazolam + Warfarin + Caffeine	Eli Lilly	Phase 1	29
Nimacimab injection + Nimacimab placebo injection + Nimacimab 300 mg injection	Skye Bioscience	Phase 2	29
Tirzepatide	Eli Lilly	Approved	50
Adenosine + Regadenoson	Astellas Pharma	Pre-clinical	26
Micafungin + Micafungin	Astellas Pharma	Approved	43
Micafungin	Astellas Pharma	Approved	43